{
  "id": 12464304,
  "title": "Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting",
  "url": "https://urgent.news/2026/10/06/bausch-lomb-advances-novel-oral-treatment-for-dry-amd-following",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-06T20:39:12.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/bausch-lomb-advances-novel-oral-treatment-for-dry-amd-following-constructive-fda-meeting"
  },
  "original_language": "en",
  "account": null,
  "summary": "BL1243 (tonabersat) is being developed as a potential oral treatment for patients with earlier-stage dry AMD, where treatment options remain limited Clinical development program expected to begin in 2027 VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}